These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32976576)

  • 41. Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study.
    Carpenter PA; Kang HJ; Yoo KH; Zecca M; Cho B; Lucchini G; Nemecek ER; Schultz KR; Stepensky P; Chaudhury S; Oshrine B; Khaw SL; Harris AC; Verna M; Zubarovskaya L; Lee Y; Wahlstrom J; Styles L; Shaw PJ; Dalle JH
    Transplant Cell Ther; 2022 Nov; 28(11):771.e1-771.e10. PubMed ID: 36044977
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China.
    Wang Y; Wu D; Zhang X; Li Y; He Y; Liu Q; Xuan L; Li Z; Qi K; Sun Y; Wang S; Mo W; Gao L; Hua Y; Wang Y; Zhang Y
    BMC Med; 2024 Mar; 22(1):142. PubMed ID: 38532458
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
    Waller EK; Miklos D; Cutler C; Arora M; Jagasia MH; Pusic I; Flowers MED; Logan AC; Nakamura R; Chang S; Clow F; Lal ID; Styles L; Jaglowski S
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2002-2007. PubMed ID: 31260802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma.
    Abdallah AO; Mohyuddin GR; Mahmoudjafari Z; Atrash S; Kawsar H; Sigle M; Shune L; McGuirk J; Ganguly S
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e212-e219. PubMed ID: 33051166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
    Roziaková L; Mistrík M; Bátorová A
    Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics.
    Li Y; Wang X; Liu L; Zhang C; Gomez D; Reyes J; Palmisano M; Zhou S
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):346-354. PubMed ID: 29746728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
    Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus.
    Lutz M; Kapp M; Einsele H; Grigoleit GU; Mielke S
    Clin Transplant; 2014 Dec; 28(12):1410-5. PubMed ID: 25287756
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
    Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.
    Bhatt VR; Shostrom VK; Choe HK; Hamilton BK; Gundabolu K; Maness LJ; Kumar V; Mahato RI; Smith LM; Nishihori T; Lee SJ
    J Clin Oncol; 2024 Nov; 42(33):3977-3985. PubMed ID: 39151112
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
    Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
    Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and Safety of Ibrutinib for Chronic Graft-Versus-Host Disease: A Systematic Review.
    Santosa D; Rizky D; Tandarto K; Kartiyani I; Yunarvika V; Ardini DNE; Setiawan B; Pangarsa EA; Suharti C
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4025-4033. PubMed ID: 38156834
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.
    Badros A; Hyjek E; Ma N; Lesokhin A; Dogan A; Rapoport AP; Kocoglu M; Lederer E; Philip S; Milliron T; Dell C; Goloubeva O; Singh Z
    Blood; 2017 Sep; 130(10):1189-1197. PubMed ID: 28461396
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
    Whangbo JS; Nikiforow S; Kim HT; Wahl J; Reynolds CG; Rai SC; Kim S; Burden A; Alho AC; Lacerda JF; Alyea EP; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J; Koreth J
    Blood Adv; 2022 Nov; 6(21):5786-5796. PubMed ID: 35475885
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pomalidomide for the management of refractory multiple myeloma.
    Summers BB; Cole SW; Olin JL
    Am J Health Syst Pharm; 2014 Sep; 71(17):1443-8. PubMed ID: 25147167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients.
    Milani P; Sharpley F; Schönland SO; Basset M; Mahmood S; Nuvolone M; Kimmich C; Foli A; Sachchithanantham S; Merlini G; Wechalekar A; Palladini G; Hegenbart U
    Amyloid; 2020 Dec; 27(4):231-236. PubMed ID: 32449385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.
    Baek DW; Cho HJ; Kim JH; Ahn JS; Kim HJ; Lim SN; Cheong JW; Kim SY; Lee HS; Won JH; Yhim HY; Sohn SK; Moon JH
    Cell Transplant; 2022; 31():9636897221113789. PubMed ID: 35861214
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.
    Dimopoulos M; Weisel K; van de Donk NWCJ; Ramasamy K; Gamberi B; Streetly M; Offidani M; Bridoux F; de la Rubia J; Mateos MV; Ardizzoia A; Kueenburg E; Collins S; Di Micco A; Rosettani B; Li Y; Bacon P; Sonneveld P
    J Clin Oncol; 2018 Jul; 36(20):2035-2043. PubMed ID: 29394124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.
    McIver Z; Stephens N; Grim A; Barrett AJ
    Biol Blood Marrow Transplant; 2010 Nov; 16(11):1549-56. PubMed ID: 20580848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.